ALX Oncology (NASDAQ:ALXO) stock fell 16% Thursday after the company reported updated data from a Phase 2 study called ASPEN-06 for its drug candidate evorpacept.
ALX said the data showed evorpacept generated a durable clinical response and exhibited a well-tolerated safety profile in patients with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer, according to a statement.
The updated results are scheduled to be presented Thursday at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.